Physician profile
Richard Hammond
NPI 1174541742
$706,812.04
in general payments reported to CMS, 2019-2025
84 companies · $86K in 2025
The $86K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $45K · 2021: $133K · 2022: $119K · 2023: $149K · 2024: $90K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $177K · Consulting Fee: $76K · Travel and Lodging: $29K · Honoraria: $25K · Food and Beverage: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $176,912.50 |
| Consulting Fee | $76,070.00 |
| Travel and Lodging | $29,076.94 |
| Honoraria | $24,950.00 |
| Food and Beverage | $15,505.31 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Education | $296.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $198,626.13 | 2019-2025 | Mavenclad, Mavenclad |
| Jazz Pharmaceuticals INC. | $181,265.07 | 2019-2025 | |
| Axsome Therapeutics, INC. | $103,642.00 | 2022-2025 | Sunosi |
| Abbvie INC. | $84,636.24 | 2021-2025 | |
| Genzyme Corporation | $61,189.36 | 2019-2025 | |
| Allergan, INC. | $20,890.32 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $15,906.48 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $15,277.72 | 2020-2024 | Wakix |
| Janssen Pharmaceuticals, INC | $13,760.88 | 2021-2022 | |
| Biogen, INC. | $1,848.01 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Inspire Medical Systems, INC. | $1,263.09 | 2019-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $749.30 | 2019-2025 | |
| Genentech USA, INC. | $727.27 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Xolair |
| Teva Pharmaceuticals USA, INC. | $719.65 | 2019-2022 | |
| Celgene Corporation | $632.38 | 2021-2025 | Zeposia |
Show all 84 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.